Chloroquine and hydroxychloroquine in the context of COVID-19

Ashutosh M Shukla MD, Lennox K Archibald MD, Aparna Wagle Shukla MD, Hiren J Mehta MD, Kartikeya Cherabuddi MD

Abstract

Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/ hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.

Article Details

Article Type

Review

DOI

10.7573/dic.2020-4-5

Categories

Publication Dates

Accepted: ; Published: .

Citation

Shukla AM, Archibald LK, Wagle Shukla A, Mehta HJ, Cherabuddi K. Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in Context 2020; 9: 2020-4-5. DOI: 10.7573/dic.2020-4-5.

Article Views

Monthly article views (last 12 months)

Drugs in Context PubMed Central
Source HTML views PDF downloads Totals
Drugs in Context since September 15, 2025 245 2 247
PubMed Central since November 1, 2024 28 21 49
Totals 273 23 294
Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.